BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Said A, Ghufran A. Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma. World J Clin Oncol 2017; 8(6): 429-436 [PMID: 29291167 DOI: 10.5306/wjco.v8.i6.429] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 48] [Article Influence: 10.4] [Reference Citation Analysis]
Number Citing Articles
1 Tao G, Zhang G, Chen W, Yang C, Xue Y, Song G, Qin S. A randomized, placebo-controlled clinical trial of hydrogen/oxygen inhalation for non-alcoholic fatty liver disease. J Cell Mol Med 2022. [PMID: 35734974 DOI: 10.1111/jcmm.17456] [Reference Citation Analysis]
2 Putzer D, Schullian P, Braunwarth E, Fodor M, Primavesi F, Cardini B, Resch T, Oberhuber R, Maglione M, Margreiter C, Schneeberger S, Stättner S, Öfner-Velano D, Jaschke W, Bale RJ. Integrating interventional oncology in the treatment of liver tumors. Eur Surg 2018;50:117-24. [PMID: 29875800 DOI: 10.1007/s10353-018-0521-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
3 Shigematsu Y, Kanda H, Amori G, Takahashi Y, Takazawa Y, Inamura K. Nonalcoholic non-virus-related hepatocellular carcinoma arising from nonsteatotic liver: Clinical and pathological features. Medicine (Baltimore) 2022;101:e28746. [PMID: 35119029 DOI: 10.1097/MD.0000000000028746] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Schou AS, Nielsen JE, Askeland A, Jørgensen MM. Extracellular vesicle-associated proteins as potential biomarkers. Adv Clin Chem 2020;99:1-48. [PMID: 32951635 DOI: 10.1016/bs.acc.2020.02.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Sharma R. Descriptive epidemiology of incidence and mortality of primary liver cancer in 185 countries: evidence from GLOBOCAN 2018. Jpn J Clin Oncol 2020;50:1370-9. [PMID: 32719873 DOI: 10.1093/jjco/hyaa130] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
6 Wu S, Chen S, Lin N, Yang J. Long non-coding RNA SUMO1P3 promotes hepatocellular carcinoma progression through activating Wnt/β-catenin signalling pathway by targeting miR-320a. J Cell Mol Med 2020;24:3108-16. [PMID: 31970876 DOI: 10.1111/jcmm.14977] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
7 Lv H, Li M, Liu Y, Zhao L, Sun J, Cao D, Zeng N, Liu J, Liu Y, Bian S, Zhang P, Yang Z, Zhang Z, Wang Z. The Clinical Value and Appropriateness Criteria of Upper Abdominal Magnetic Resonance Examinations in Patients Before and After Bariatric Surgery: a Study of 837 Images. Obes Surg 2020;30:3784-91. [PMID: 32483745 DOI: 10.1007/s11695-020-04688-w] [Reference Citation Analysis]
8 Zubair T, Yen T, Gao G. Solitary Extrahepatic Intramuscular Metastasis from Cryptogenic Hepatocellular Carcinoma. ACG Case Rep J 2018;5:e64. [PMID: 30238018 DOI: 10.14309/crj.2018.64] [Reference Citation Analysis]
9 Lai SW. Risk factors for hepatocellular carcinoma. Cancer 2019;125:482. [PMID: 30500069 DOI: 10.1002/cncr.31802] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Takahashi M, Hori M, Ishigamori R, Mutoh M, Imai T, Nakagama H. Fatty pancreas: A possible risk factor for pancreatic cancer in animals and humans. Cancer Sci. 2018;109:3013-3023. [PMID: 30099827 DOI: 10.1111/cas.13766] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 6.5] [Reference Citation Analysis]
11 Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep 2021;3:100305. [PMID: 34189448 DOI: 10.1016/j.jhepr.2021.100305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Davis TME, Peters KE, Chubb SAP, Adams LA, Jeffrey GP, Davis WA. Changes in the Epidemiology of Hepatobiliary Disease Complicating Type 2 Diabetes over 25 Years: The Fremantle Diabetes Study. J Clin Med 2020;9:E3409. [PMID: 33114323 DOI: 10.3390/jcm9113409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Zhang Y, Wang C, Xu H, Xiao P, Gao Y. Hepatocellular carcinoma in the noncirrhotic liver: a literature review. Eur J Gastroenterol Hepatol 2019;31:743-8. [PMID: 31008808 DOI: 10.1097/MEG.0000000000001419] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
14 Hyun J, Al Abo M, Dutta RK, Oh SH, Xiang K, Zhou X, Maeso-Díaz R, Caffrey R, Sanyal AJ, Freedman JA, Patierno SR, Moylan CA, Abdelmalek MF, Diehl AM. Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease. J Hepatol 2021;75:623-33. [PMID: 33964370 DOI: 10.1016/j.jhep.2021.04.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Kodama T, Yi J, Newberg JY, Tien JC, Wu H, Finegold MJ, Kodama M, Wei Z, Tamura T, Takehara T, Johnson RL, Jenkins NA, Copeland NG. Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis. Proc Natl Acad Sci U S A 2018;115:E10417-26. [PMID: 30327349 DOI: 10.1073/pnas.1808968115] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
16 Izquierdo AG, Carreira MC, Amil M, Mosteiro CS, Garcia-Caballero T, Fernandez-Quintela A, Portillo MP, Casanueva FF, Crujeiras AB. An energy restriction-based weight loss intervention is able to reverse the effects of obesity on the expression of liver tumor-promoting genes. FASEB J 2020;34:2312-25. [PMID: 31908001 DOI: 10.1096/fj.201901147RR] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
17 Kim H, Lee DS, An TH, Park HJ, Kim WK, Bae KH, Oh KJ. Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. Int J Mol Sci 2021;22:4495. [PMID: 33925827 DOI: 10.3390/ijms22094495] [Reference Citation Analysis]
18 Shen T, Lu Y, Zhang Q. High Squalene Epoxidase in Tumors Predicts Worse Survival in Patients With Hepatocellular Carcinoma: Integrated Bioinformatic Analysis on NAFLD and HCC. Cancer Control 2020;27:1073274820914663. [PMID: 32216563 DOI: 10.1177/1073274820914663] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
19 Hill JH, Solt C, Foster MT. Obesity associated disease risk: the role of inherent differences and location of adipose depots. Horm Mol Biol Clin Investig 2018;33:/j/hmbci. [PMID: 29547393 DOI: 10.1515/hmbci-2018-0012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
20 Kedar Mukthinuthalapati VVP, Sewram V, Ndlovu N, Kimani S, Abdelaziz AO, Chiao EY, Abou-Alfa GK. Hepatocellular Carcinoma in Sub-Saharan Africa. JCO Glob Oncol 2021;7:756-66. [PMID: 34043413 DOI: 10.1200/GO.20.00425] [Reference Citation Analysis]
21 García-Berumen CI, Ortiz-Avila O, Vargas-Vargas MA, Del Rosario-Tamayo BA, Guajardo-López C, Saavedra-Molina A, Rodríguez-Orozco AR, Cortés-Rojo C. The severity of rat liver injury by fructose and high fat depends on the degree of respiratory dysfunction and oxidative stress induced in mitochondria. Lipids Health Dis 2019;18:78. [PMID: 30927921 DOI: 10.1186/s12944-019-1024-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
22 Cao L, Cheng H, Jiang Q, Li H, Wu Z. APEX1 is a novel diagnostic and prognostic biomarker for hepatocellular carcinoma. Aging (Albany NY). 2020;12:4573-4591. [PMID: 32167932 DOI: 10.18632/aging.102913] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
23 Thorgersen EB, Barratt-Due A, Haugaa H, Harboe M, Pischke SE, Nilsson PH, Mollnes TE. The Role of Complement in Liver Injury, Regeneration, and Transplantation. Hepatology 2019;70:725-36. [PMID: 30653682 DOI: 10.1002/hep.30508] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 18.3] [Reference Citation Analysis]
24 Pazgan-Simon M, Kukla M, Zuwała-Jagiełło J, Derra A, Bator M, Menżyk T, Lekstan A, Grzebyk E, Simon K. Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC). PLoS One 2020;15:e0227459. [PMID: 31935230 DOI: 10.1371/journal.pone.0227459] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
25 El-Daly UM, Saber MM, Abdellateif MS, Nassar HR, Namour AE, Ismail YM, Zekri AN. The Possible Role of Adipokines in HCV Associated Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2020;21:599-609. [PMID: 32212784 DOI: 10.31557/APJCP.2020.21.3.599] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
26 Song HJ, Jiang X, Henry L, Nguyen MH, Park H. Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis. Eur J Clin Pharmacol 2020;76:851-66. [PMID: 32172363 DOI: 10.1007/s00228-020-02854-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
27 Huang L, Ding W, Wang MQ, Wang ZG, Chen HH, Chen W, Yang Q, Lu TN, Yang Q, He JM. Tanshinone IIA ameliorates non-alcoholic fatty liver disease through targeting peroxisome proliferator-activated receptor gamma and toll-like receptor 4. J Int Med Res 2019;47:5239-55. [PMID: 31378113 DOI: 10.1177/0300060519859750] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
28 Abe T, Yamada D, Asukai K, Hasegawa S, Tomokuni A, Wada H, Fujii W, Ikezawa K, Fukutake N, Ohkawa K, Shinno N, Hara H, Yanagimoto Y, Takahashi Y, Sugimura K, Yamamoto K, Ushigome H, Haraguchi N, Nishimura J, Yasui M, Omori T, Miyata H, Ohue M, Yano M, Sakon M, Takahashi H. Decreased CT-number in the pancreatic parenchyma is a reliable imaging biomarker of the presence of malignancies in patients with high-risk intraductal papillary mucinous neoplasm. Pancreatology 2020;20:442-7. [PMID: 32146046 DOI: 10.1016/j.pan.2020.02.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Dhamija E, Paul SB, Kedia S. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern. Indian J Med Res. 2019;149:9-17. [PMID: 31115369 DOI: 10.4103/ijmr.ijmr_1456_17] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
30 Krishnamurthy S, Gilot D, Ahn SB, Lam V, Shin JS, Guillemin GJ, Heng B. Involvement of Kynurenine Pathway in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5180. [PMID: 34680327 DOI: 10.3390/cancers13205180] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Valenzuela R, Ortiz M, Hernández-Rodas MC, Echeverría F, Videla LA. Targeting n-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease. Curr Med Chem 2020;27:5250-72. [PMID: 30968772 DOI: 10.2174/0929867326666190410121716] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
32 Zhang M, Yuan Y, Wang Q, Li X, Men J, Lin M. The Chinese medicine Chai Hu Li Zhong Tang protects against non-alcoholic fatty liver disease by activating AMPKα. Biosci Rep 2018;38:BSR20180644. [PMID: 30291215 DOI: 10.1042/BSR20180644] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
33 Liu Z, Li Z, Xu B, Yao H, Qi S, Tai J. Long Noncoding RNA PRR34-AS1 Aggravates the Progression of Hepatocellular Carcinoma by Adsorbing microRNA-498 and Thereby Upregulating FOXO3. Cancer Manag Res 2020;12:10749-62. [PMID: 33154667 DOI: 10.2147/CMAR.S263619] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
34 Kutlu O, Kaleli HN, Ozer E. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2018;2018:8543763. [PMID: 30228976 DOI: 10.1155/2018/8543763] [Cited by in Crossref: 32] [Cited by in F6Publishing: 39] [Article Influence: 8.0] [Reference Citation Analysis]
35 Rowles JL 3rd, Han A, Miller RJ, Kelly JR, Applegate CC, Wallig MA, O'Brien WD Jr, Erdman JW Jr. Low fat but not soy protein isolate was an effective intervention to reduce nonalcoholic fatty liver disease progression in C57BL/6J mice: monitored by a novel quantitative ultrasound (QUS) method. Nutr Res 2019;63:95-105. [PMID: 30824402 DOI: 10.1016/j.nutres.2018.12.003] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
36 Kim M, Rho Y, Park R, Jung J, Hwang GS, Seo YK, Seo JH, Heo Y, Ha TK, Ha E. Duodenal-jejunal bypass maintains hepatic S-adenosylmethionine/S-homocysteine ratio in diet-induced obese rats. Surg Obes Relat Dis 2021;17:1359-68. [PMID: 33753007 DOI: 10.1016/j.soard.2021.02.011] [Reference Citation Analysis]
37 Liao L, Duan D, Liu Y, Chen L. LHPP inhibits hepatocellular carcinoma cell growth and metastasis. Cell Cycle 2020;19:1846-54. [PMID: 32578511 DOI: 10.1080/15384101.2020.1783472] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
38 Azit NA, Sahran S, Voon Meng L, Subramaniam M, Mokhtar S, Mohammed Nawi A. Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country. PLoS One 2021;16:e0260675. [PMID: 34882716 DOI: 10.1371/journal.pone.0260675] [Reference Citation Analysis]
39 Gurses SA, Banskar S, Stewart C, Trimoski B, Dziarski R, Gupta D. Nod2 protects mice from inflammation and obesity-dependent liver cancer. Sci Rep 2020;10:20519. [PMID: 33239685 DOI: 10.1038/s41598-020-77463-7] [Reference Citation Analysis]
40 Said I, Ahad H, Said A. Gut microbiome in non-alcoholic fatty liver disease associated hepatocellular carcinoma: Current knowledge and potential for therapeutics. World J Gastrointest Oncol 2022; 14(5): 947-958 [DOI: 10.4251/wjgo.v14.i5.947] [Reference Citation Analysis]
41 Kumar R, Priyadarshi RN, Anand U. Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations. J Clin Transl Hepatol 2020;8:76-86. [PMID: 32274348 DOI: 10.14218/JCTH.2019.00051] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
42 Léveillé M, Estall JL. Mitochondrial Dysfunction in the Transition from NASH to HCC. Metabolites 2019;9:E233. [PMID: 31623280 DOI: 10.3390/metabo9100233] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
43 German MN, Lutz MK, Pickhardt PJ, Bruce RJ, Said A. Statin Use is Protective Against Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Case-control Study. Journal of Clinical Gastroenterology 2020;54:733-40. [DOI: 10.1097/mcg.0000000000001260] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
44 Lake AD, Hardwick RN, Leamon CP, Low PS, Cherrington NJ. Folate receptor-beta expression as a diagnostic target in human & rodent nonalcoholic steatohepatitis. Toxicol Appl Pharmacol 2019;368:49-54. [PMID: 30794826 DOI: 10.1016/j.taap.2019.02.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Steffen IG, Weissmann T, Rothe JH, Geisel D, Chopra SS, Kahn J, Hamm B, Denecke T. Does Hepatic Steatosis Influence the Detection Rate of Metastases in the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI? J Clin Med 2020;10:E98. [PMID: 33396634 DOI: 10.3390/jcm10010098] [Reference Citation Analysis]
46 Kornberg A, Friess H. 18F-fludeoxyglucose positron emission tomography for diagnosis of HCC: implications for therapeutic strategy in curative and non-curative approaches. Therap Adv Gastroenterol 2019;12:1756284819836205. [PMID: 30915167 DOI: 10.1177/1756284819836205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Chen S, Chao S, Konerman M, Zhang W, Rao H, Wu E, Lin A, Wei L, Lok AS. Survey of Nonalcoholic Fatty Liver Disease Knowledge, Nutrition, and Physical Activity Patterns Among the General Public in Beijing, China. Dig Dis Sci 2019;64:3480-8. [PMID: 31273595 DOI: 10.1007/s10620-019-05709-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
48 Hsu CL, Wu FZ, Lin KH, Chen YH, Wu PC, Chen YH, Chen CS, Wang WH, Mar GY, Yu HC. Role of Fatty Liver Index and Metabolic Factors in the Prediction of Nonalcoholic Fatty Liver Disease in a Lean Population Receiving Health Checkup. Clin Transl Gastroenterol. 2019;10:1-8. [PMID: 31082856 DOI: 10.14309/ctg.0000000000000042] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
49 Liu X, Ju W, Huo C, Zhang S, Wang X, Huang K. Overweight and Obesity as Independent Factors for Increased Risk of Hepatocellular Cancer-Related Mortality: A Meta-Analysis. J Am Coll Nutr 2021;40:287-93. [PMID: 32281914 DOI: 10.1080/07315724.2020.1751007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Samji NS, Verma R, Keri KC, Singal AK, Ahmed A, Rinella M, Bernstein D, Abdelmalek MF, Satapathy SK. Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges. Dig Dis Sci 2019;64:3413-30. [PMID: 31312990 DOI: 10.1007/s10620-019-05716-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
51 Tomasiewicz K, Flisiak R, Halota W, Jaroszewicz J, Lebensztejn D, Lisik W, Małkowski P, Pawłowska M, Piekarska A, Simon K, Tronina O; Recommendations of the Polish Group of Experts for Non-Alcoholic Fatty Liver Disease (PGE-NAFLD). Recommendations for the management of non-alcoholic fatty liver disease (NAFLD). Clin Exp Hepatol 2018;4:153-7. [PMID: 30324139 DOI: 10.5114/ceh.2018.78118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
52 de Avila V, Paik JM, de Avila L, Henry L, Mohess D, Roche-Green A, Younossi ZM. Hospice care utilisation among elderly patients who died with hepatocellular carcinoma in the United States. JHEP Rep 2021;3:100236. [PMID: 33748729 DOI: 10.1016/j.jhepr.2021.100236] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]